JBI-802 Shows Early Platelet Control in MPNs
In the first clinical disclosure from an ongoing Phase I/II study, oral JBI-802 produced rapid platelet-count reductions across essential thrombocythemia, polycythemia vera, myelofibrosis, and MDS/MPN with thrombocytosis. Nine of nine evaluable ET or PV…
